Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy

A Correction to this article was published on 20 May 2020

This article has been updated

Abstract

Purpose

To evaluate the effectiveness of steroid-pulse therapy and three-wall orbital decompression in patients with dysthyroid optic neuropathy (DON).

Methods

Twenty-five patients (46 eyes) with a diagnosis of DON between 2008 and 2015 were included in the study. The first group (7 patients, 16 eyes) consisted of patients with a steroid-pulse treatment only and the second group (18 patients, 30 eyes) included patients with medical and surgical decompression.

Results

Twenty patients were female; five patients were male. After the diagnosis of DON, all patients were treated with steroid-pulse treatment (intravenous 500 mg prednisolon twice/week for 4 weeks, 250 mg twice/week for 2 weeks) as a first-line treatment (medical decompression). In 30 eyes (18 patients) out of 46 eyes, (25 patients) an orbital decompression was needed to preserve the optic nerve function. In those therapy-resistant cases (surgical decompression group), the orbital decompression led to statistically significant improvements in best-corrected visual acuity (BCVA), protan and tritan value of the color vision (p = 0.007, p < 0.0001, p = 0.019, respectively, comparison of first visit to last visit).

Conclusion

According to our data, the mild cases of DON with better initial visual acuity (in our case series mean: 0.3 logMAR) seem to respond well to steroid treatment. However, therapy-resistant cases with an impaired initial BCVA (in our case series, mean: 0.6 logMAR) seem to need the surgery to preserve the optic nerve function. In conclusion, this retrospective study confirms the effectiveness of surgical decompression in therapy-resistant cases of DON.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 20 May 2020

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

  1. 1.

    Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev. 1993;14:747–93.

    CAS  PubMed  Google Scholar 

  2. 2.

    Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N. Engl J Med. 1993;329:1468–75.

    CAS  Article  Google Scholar 

  3. 3.

    Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18:333–46.

    Article  Google Scholar 

  4. 4.

    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14.

    CAS  Article  Google Scholar 

  5. 5.

    Berninger T, Drobner B, Hogg C, Rudolph G, Arden GB, Kampik A. [Color vision in relation to age: a study of normal values]. Klin Monbl Augenheilkd. 1999;215:37–42.

    CAS  Article  Google Scholar 

  6. 6.

    Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–99.

    CAS  PubMed  Google Scholar 

  7. 7.

    Guy JR, Fagien S, Donovan JP, Rubin ML. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology. 1989;96:1048–52. discussion 52-3

    CAS  Article  Google Scholar 

  8. 8.

    Ph Mourits M, Kalmann R, Sasim IV. Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy. Orbit. 2001;20:275–80.

    Article  Google Scholar 

  9. 9.

    Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–40.

    CAS  Article  Google Scholar 

  10. 10.

    Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96:320–32.

    CAS  Article  Google Scholar 

  11. 11.

    Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf). 2005;63:323–8.

    CAS  Article  Google Scholar 

  12. 12.

    Curro N, Covelli D, Vannucchi G, Campi I, Pirola G, Simonetta S, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid. 2014;24:897–905.

    CAS  Article  Google Scholar 

  13. 13.

    Garrity JA, Fatourechi V, Bergstralh EJ, Bartley GB, Beatty CW, DeSanto LW, et al. Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy. Am J Ophthalmol. 1993;116:533–47.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Aylin Garip Kuebler.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Garip Kuebler, A., Wiecha, C., Reznicek, L. et al. Evaluation of medical and surgical decompression in patients with dysthyroid optic neuropathy. Eye 34, 1702–1709 (2020). https://doi.org/10.1038/s41433-020-0897-x

Download citation

Further reading

Search

Quick links